RA Capital Management’s Climb Bio CLYM Stock Holding History

RA Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147M	Hold	11,300,939	–	–	1.28%	24
2026 Q1	$77.4M	Buy	11,300,939 +7,111	+0.1%	+$41K	0.82%	28
2025 Q4	$77.7M	Sell	11,293,828 -20,125,439	-64%	-$48.3M	0.8%	25
2025 Q3	$63.2M	Hold	31,419,267	–	–	0.78%	29
2025 Q2	$39M	Hold	31,419,267	–	–	0.66%	30
2025 Q1	$38.3M	Hold	31,419,267	–	–	0.64%	28
2024 Q4	$56.6M	Hold	31,419,267	–	–	0.75%	28
2024 Q3	$160M	Hold	31,419,267	–	–	1.84%	14
2024 Q2	$223M	Buy	31,419,267 +18,268,418	+139%	+$122M	2.95%	7
2024 Q1	$36M	Hold	13,150,849	–	–	0.46%	48
2023 Q4	$35.5M	Hold	13,150,849	–	–	0.55%	37
2023 Q3	$34.6M	Hold	13,150,849	–	–	0.68%	40
2023 Q2	$36.8M	Hold	13,150,849	–	–	0.7%	38
2023 Q1	$38.1M	Hold	13,150,849	–	–	0.86%	35
2022 Q4	$48.3M	Hold	13,150,849	–	–	0.98%	30
2022 Q3	$42.5M	Hold	13,150,849	–	–	0.91%	37
2022 Q2	$39.7M	Hold	13,150,849	–	–	1.06%	31
2022 Q1	$110M	Hold	13,150,849	–	–	2.41%	9
2021 Q4	$138M	Hold	13,150,849	–	–	2.43%	8
2021 Q3	$236M	Buy	+13,150,849	New	+$272M	3.28%	3

Other funds holding CLYM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

RA Capital Management's CLYM Position: Q2 2026 in Review

RA Capital Management held its Climb Bio (CLYM) position steady in Q2 2026 at 11,300,939 shares worth $147M. The position accounts for 1.28% of the portfolio, ranked #24.

RA Capital Management first reported a position in CLYM in Q3 2021 and has held it in 20 quarters since. The position peaked at $236M in Q3 2021. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

RA Capital Management held 11,300,939 shares of Climb Bio worth $147M as of Q2 2026.
RA Capital Management left its Climb Bio share count unchanged in Q2 2026.
Climb Bio made up 1.28% of RA Capital Management's portfolio in Q2 2026, its #24 holding.
RA Capital Management first reported a position in Climb Bio in Q3 2021 and has held it in 20 quarters since.
RA Capital Management's Climb Bio position peaked at $236M in Q3 2021.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.